The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Open accessAbstract
There exists a tremendous opportunity in identifying and determining the appropriate predictive and prognostic biomarker(s) for risk stratification of patients with colorectal cancers (CRCs). Circulating tumor DNA (ctDNA) has emerged as a promising prognostic and possibly predictive biomarker in the personalized management of patients with CRCs. The disease is particularly suited to a liquid biopsy–based approach since there is a great deal of shedding of circulating tumor fragments (cells, DNA, methylation markers, etc). ctDNA has been shown to have several potential applications, including detecting minimal residual disease (MRD), monitoring for early recurrence, molecular profiling, and therapeutic response prediction. The utility of ctDNA has broadened from its initial use in the advanced/metastatic setting for molecular profiling and detection of acquired resistance mechanisms, toward identifying MRD, as well as early detection. Prospective studies such as CIRCULATE, COBRA, Dynamic II/III, and ACT3 are underway in the MRD setting to further understand how ctDNA may be used to inform clinical decision making using both tumor-informed and tumor-agnostic platforms. These prospective studies use ctDNA to guide management of patients with CRC and will be critical to help guide how and where ctDNA should or should not be used in clinical decision making. It is also important to understand that there are different types of ctDNA liquid biopsy platforms, each with advantages and disadvantages in different clinical indications. This review provides an overview of the current and evolving use of ctDNA in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · cited 2×
“…to Convert ctDNA-Positive to ctDNA-Negative (% of ctDNA clearance postoperatively) Reinert et al25 I-III 3/10 (30) Parikh et al15 I-III 1/6 (16.7) Tie et al16 II 3/6 (50) Tie et al17 III 5/20 (25) Henriksen et al18 III 4/20 (20) Tie et al20 IV 3/11 (27.3) Kotaka et al24 I-IV 65/96…”
BackgroundInfluentialClonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H., Knudsen, M., Nordentoft, I., Wu, H.-T., Tin, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0528 · Cited by 1,011
Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 945
De Mattos-Arruda, L., Mayor, R., Ng, C. K. Y., Weigelt, B., Martínez-Ricarte, F., Torrejon, D., Oliveira, M., Arias, A., Raventos, C., Tang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9839 · Cited by 865
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3616 · Cited by 668
Biagi, J. J., Raphael, M. J., Mackillop, W. J., Kong, W., King, W. D., & Booth, C. M. (2011) · JAMA · doi:10.1001/jama.2011.749 · Cited by 632
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518
Self-citationWang, Y., Springer, S., Mulvey, C. L., Silliman, N., Schaefer, J., Sausen, M., James, N., Rettig, E. M., Guo, T., Pickering, C. R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8507 · Cited by 500
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487 · cited 1×
“Response prediction to immunotherapy using ctDNA has shown promise in the INSPIRE study, a prospective phase II trial that followed 94 patients with 25 advanced solid tumor types treated with pembrolizumab with serial ctDNA assessments.(44) ctDNA increase at 6 weeks with increasing tumor volume was seen in 42% of the…”
MethodCremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0410 · Cited by 380
Self-citationNakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373
Dasari, A., Morris, V. K., Allegra, C. J., Atreya, C., Benson, A. B., Boland, P., Chung, K., Copur, M. S., Corcoran, R. B., Deming, D. A., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0392-0 · Cited by 372
Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0047 · Cited by 348
Vidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Overman, M. J., Modak, J., Kopetz, S., Murthy, R., Yao, J. C., Hicks, M. E., Abbruzzese, J. L., & Tam, A. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1718 · Cited by 314
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 299
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.035 · Cited by 287
Henriksen, T. V., Tarazona, N., Frydendahl, A., Reinert, T., Gimeno-Valiente, F., Carbonell-Asins, J. A., Sharma, S., Renner, D., Hafez, D., Roda, D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2404 · Cited by 261
Morelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar, E., Johnson, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 253
Self-citationAnalysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients
Diehl, F., Schmidt, K., Durkee, K. H., Moore, K. J., Goodman, S. N., Shuber, A. P., Kinzler, K. W., & Vogelstein, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.039 · Cited by 228
Andre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.18_suppl.lba4 · Cited by 194
Osterman, E., & Glimelius, B. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001158 · Cited by 192
Tie, J., Wang, Y., Cohen, J., Li, L., Hong, W., Christie, M., Wong, H. L., Kosmider, S., Wong, R., Thomson, B., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003620 · Cited by 180
Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
Chakrabarti, S., Peterson, C. Y., Sriram, D., & Mahipal, A. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i8.808 · Cited by 174
Henriksen, T. V., Reinert, T., Christensen, E., Sethi, H., Birkenkamp‐Demtröder, K., Gögenur, M., Gögenur, I., Zimmermann, B. G., The IMPROVE Study Group, Dyrskjøt, L., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12729 · Cited by 168
Loupakis, F., Sharma, S., Derouazi, M., Murgioni, S., Biason, P., Rizzato, M. D., Rasola, C., Renner, D., Shchegrova, S., Malashevich, A. K., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00101 · Cited by 146
"Liquid biopsy"-ctDNA detection with great potential and challenges.
Ma, M., Zhu, H., Zhang, C., Sun, X., Gao, X., & Chen, G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.09.29 · Cited by 144
Wilkinson, N. W., Yothers, G., Lopa, S., Costantino, J. P., Petrelli, N. J., & Wolmark, N. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0881-y · Cited by 143
Parikh, A. R., Mojtahed, A., Schneider, J. L., Kanter, K. N., Seventer, E. E. V., Fetter, I. J., Thabet, A., Fish, M. G., Teshome, B., Fosbenner, K. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3467 · Cited by 142
Self-citationKimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K., & Nishio, K. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603428 · Cited by 141
Vidal, J., Casadevall, D., Bellosillo, B., Pericay, C., García‐Carbonero, R., Losa, F., Layos, L., Alonso, V., Capdevila, J., Gallego-Plazas, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4769 · Cited by 105
Kagawa, Y., Élez, E., García‐Foncillas, J., Bando, H., Taniguchi, H., Vivancos, A. P., Akagi, K., García, A., Denda, T., Ros, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3677 · Cited by 88
Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T., & Zembutsu, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1913 · Cited by 87
Taı̈eb, J., Taly, V., Vernerey, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.019 · Cited by 68
Bianchi, A. S., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Fenocchio, E., Amatu, A., Corallo, S., Manai, C., Tosi, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3506 · Cited by 68
Kotaka, M., Shirasu, H., Watanabe, J., Yamazaki, K., Hirata, K., Akazawa, N., Matsuhashi, N., Yokota, M., Ikeda, M., Kato, K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.009 · Cited by 63
Bos, M. K., Nasserinejad, K., Jansen, M. P. H. M., Steendam, C. M. J., Angus, L., Atmodimedjo, P. N., de Jonge, E., Dinjens, W. N. M., van Schaik, R. H. N., Re, M. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12827 · Cited by 61
Kasi, P. M., Budde, G. L., Krainock, M. R., Aushev, V. N., Malashevich, A. K., Malhotra, M., Olshan, P., Billings, P. R., & Aleshin, A. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003312 · Cited by 49
Self-citationAnandappa, G., Starling, N., Begum, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.102 · Cited by 31
Lonardi, S., Nimeiri, H. S., Xu, C., Zollinger, D. R., Madison, R. W., Fine, A. D., Gjoerup, O. V., Rasola, C., Angerilli, V., Sharma, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911529 · Cited by 30
Kalashnikova, E. V., Aushev, V. N., Malashevich, A. K., Tin, A. S., Krinshpun, S., Salari, R., Scalise, C. B., Ram, R. R., Malhotra, M., Ravi, H., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13557 · Cited by 29
Tarazona, N., Henriksen, T. V., Carbonell‐Asins, J. A., Reinert, T., Sharma, S., Roda, D., Shchegrova, S., Huerta, M., Roselló, S., Renner, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4009 · Cited by 19
Commentary on tumor heterogeneity
Popper, H. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.08.07 · Cited by 14
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., Kim, A. H., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102697 · Cited by 37
“11,12 Tumor-agnostic assays utilize an “ off-the-shelf ” uniform panel and are more widely adopted in AML and lung cancer, where patients harbor a limited set of mutated genes.”
MethodAnti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
“Its sensitivity is affected by tumor biology and assay performance [156–158].”
The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology
Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16040523 · Cited by 14
Metadata
- Authors
- Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-08-20
- Volume
- 40
- Issue
- 24
- Pages
- 2846-2857
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4285492196
- Cited by
- 292
- References
- 54
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.